Norristown, PA, United States of America

Timothy Nacarelli

This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Drexel University. Active years: 2020-2026.

USPTO Granted Patents = 3 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2020-2026

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Timothy Nacarelli

Introduction

Timothy Nacarelli is an accomplished inventor based in Norristown, PA (US). He has made significant contributions to the field of dermatology through his innovative patents. With a total of 3 patents, Nacarelli's work focuses on developing effective treatments for various dermal disorders.

Latest Patents

Nacarelli's latest patents include compositions and methods for treating or preventing dermal disorders. These inventions address conditions such as dermal atrophy, pseudoscars, actinic keratosis, and coarse wrinkles. The compositions involve a therapeutically effective amount of a mTORC1 inhibitor combined with a dermatologically acceptable carrier, showcasing his commitment to advancing dermatological treatments.

Career Highlights

Timothy Nacarelli is affiliated with Drexel University, where he continues to contribute to research and innovation in dermatology. His work has garnered attention for its potential to improve the quality of life for individuals suffering from various skin conditions.

Collaborations

Nacarelli collaborates with notable colleagues, including Christian Sell and Ashley Azar, to further enhance the impact of his research and inventions.

Conclusion

Timothy Nacarelli's innovative contributions to dermatology through his patents reflect his dedication to improving skin health. His work continues to inspire advancements in the treatment of dermal disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…